Colombia forces Novartis to reduce cancer drug price

13-06-2016

Colombia forces Novartis to reduce cancer drug price

lucarista / Shutterstock.com

Colombia’s government will set a new price for Novartis’s cancer drug Gleevec (imatinib) following a recent dispute.


Patent, Colombia, Gleevec, compulsory licence, imatinib

LSIPR